Latest news

How about an opportunity to assess your compounds in a comprehensive and cost-effective manner? Explicyte is planning a new in vivo shuttle session by mid March, to be held on a series of either subcutaneously- or orthotopically-inoculated syngeneic tumor mouse models.

We will be attending the ESMO Immuno-Oncology Congress in Geneva, from December 11 to 14, 2019. We are glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.

Explicyte is planning a new in vivo shuttle session by mid-November that can be held on a series of syngeneic tumor mouse models. This shuttle session can focus either on only an in vivo efficacy monitoring or on a comprehensive assessment relying on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.

Explicyte was pleased to participate in the AACR Virtual Annual Meeting to get breakthroughs in Immuno-Oncology and to present our posters featuring our capacities that support drug discovery.

By setting new facilities within the cancer center “Institut Bergonié”, Explicyte strengthens its development towards clinical translational research, to provide new services based on multiparametric experimental biomarker analysis, for target identification and monitoring of the immune response in the context of clinical trials.

We will be attending the AACR Annual Meeting in Atlanta, from March 29 to April 3, 2019. We will be glad to take this opportunity to meet you there, describe our service offerings and approach your research projects.